For a retired patient with mild obstructive sleep apnea on PAP therapy and persistent insomnia despite trials of doxepin, hydroxyzine, Belsomra (suvorexant), and Dayvigo, which dual orexin receptor antagonist (DORA) medication should be tried?

Recommendation for DORA Selection

Given your patient's mild OSA on PAP therapy and persistent sleep maintenance insomnia, I recommend trying lemborexant (Dayvigo) as your next DORA agent, starting at 5 mg with potential titration to 10 mg if needed. 1

Rationale for Lemborexant Over Suvorexant

Your patient has already attempted both Belsomra (suvorexant) and Dayvigo (lemborexant), but insurance authorization issues prevented ongoing use of both. Since the patient briefly trialed these medications previously, the key question is which one to pursue more aggressively for insurance approval or which alternative to consider.

Why Lemborexant is the Preferred Choice:

For patients with comorbid OSA and insomnia, lemborexant demonstrates superior respiratory safety data. The most recent 2024 study specifically evaluated lemborexant 10 mg in patients with moderate to severe OSA (more severe than your patient's mild OSA with AHI 12/hr) and found no significant differences in AHI or oxygen saturation after both single and multiple doses 2. This is particularly reassuring given your patient's OSA diagnosis.

Lemborexant has demonstrated efficacy for sleep maintenance insomnia specifically. Recent meta-analyses show lemborexant 10 mg produces a standardized mean difference of -0.430 for subjective time to sleep onset and improves total sleep time, which directly addresses your patient's primary complaint of nighttime awakenings and difficulty returning to sleep 3.

Safety Considerations with OSA:

While suvorexant is mentioned in the 2017 AASM guidelines for sleep maintenance insomnia 4, the FDA label for Belsomra specifically notes that in patients with mild to moderate OSA, the mean AHI treatment difference was 2.7 events/hour with "wide inter- and intra-individual variability such that clinically meaningful respiratory effects cannot be excluded" 5.

In contrast, lemborexant showed NO significant differences in AHI in patients with even more severe OSA than your patient has 2. A 2024 meta-analysis of all DORAs in OSA patients confirmed that DORAs as a class do not impair nighttime respiratory function, but lemborexant has the most robust safety data in this population 6.

Practical Implementation:

Dosing Strategy:

• Start with lemborexant 5 mg taken within 30 minutes of bedtime with at least 7 hours remaining before planned awakening
• Titrate to 10 mg if 5 mg is insufficient after 1-2 weeks of consistent use
• The lower starting dose minimizes next-day somnolence risk while still providing therapeutic benefit

What to Monitor:

• Sleep maintenance specifically: Track middle-of-the-night awakenings and ability to return to sleep
• Next-day effects: Your patient experienced "down" and "blah" feelings with doxepin 6 mg, so monitor for any residual morning sedation or mood effects
• PAP adherence: Ensure continued PAP use, as the combination is safe and the patient is already noting benefit from PAP
• Falls risk: Though your patient is retired and relatively young (weight 158 lbs suggests not elderly), somnolence can increase fall risk

Insurance Authorization Strategy:

Since insurance previously blocked both Belsomra and Dayvigo, you'll need to:

• Document failed trials: Doxepin (3 mg and 6 mg - inadequate efficacy/tolerability), hydroxyzine (current use suggests inadequate efficacy), nortriptyline, clonazepam
• Emphasize comorbid OSA: Lemborexant has the strongest safety data for patients with OSA, which is a compelling medical necessity argument 2
• Highlight sleep maintenance insomnia: This is the FDA-approved indication for lemborexant 1

Alternative if Lemborexant Remains Unavailable:

If insurance continues to deny lemborexant, pursue daridorexant as a third-line DORA option. Recent 2025 expert consensus specifically endorses daridorexant for patients with comorbid insomnia and sleep apnea 7, and it has demonstrated safety in mild-moderate OSA 8. However, daridorexant is newer with less extensive real-world data than lemborexant.

Why Not Suvorexant:

While suvorexant is guideline-supported 4, the FDA label's explicit caution about "clinically meaningful respiratory effects that cannot be excluded" in OSA patients 5 makes it a less optimal choice when lemborexant has cleaner safety data in this specific population.

Key Clinical Pearls:

• DORAs work differently than doxepin: Your patient's negative experience with doxepin (antihistamine/anticholinergic effects causing next-day "blah" feeling) does not predict DORA response, as DORAs work by blocking wake-promoting orexin signaling rather than sedation 9
• No tolerance or withdrawal: Unlike benzodiazepines or Z-drugs, DORAs don't cause physiological tolerance or rebound insomnia upon discontinuation 3
• Long-term safety: Recent 2026 meta-analysis confirms DORAs maintain efficacy and acceptable safety profiles at 6-12 months 10
• Timing with PAP: The patient can use lemborexant and PAP simultaneously - the 2024 meta-analysis specifically confirmed DORAs don't worsen OSA parameters 6

The combination of your patient's mild OSA on PAP therapy, sleep maintenance insomnia pattern, and prior medication intolerances makes lemborexant the most evidence-based choice among available DORAs.